Alessandra Soriano

Azienda Sanitaria Unità Locale di Reggio Emilia

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Carlo Salvarani

Azienda Sanitaria Unità Locale di Reggio Emilia

Maurizio Zizzo

Azienda Sanitaria Unità Locale di Reggio Emilia

Raffaele Manna

Agostino Gemelli University Polyclinic

Stefano Ascani

University of Perugia

Francesca Sanguedolce

Ospedali Riuniti di Foggia

Magda Zanelli

Azienda Sanitaria Unità Locale di Reggio Emilia

Yehuda Shoenfeld

Sheba Medical Center

Andrea Palicelli

Azienda Sanitaria Unità Locale di Reggio Emilia

Luca Cimino

University of Modena and Reggio Emilia

Stefania Croci

Azienda Sanitaria Unità Locale di Reggio Emilia

Cooperative Institutions

Istituti di Ricovero e Cura a Carattere Scientifico

222

Center for Rheumatology

137

Sapienza University of Rome

Azienda Sanitaria Unità Locale di Reggio Emilia

Università Cattolica del Sacro Cuore

Ospedale Santa Maria

Tel Aviv University

University of Milan

Sheba Medical Center

Universitat de Barcelona

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Su1940 – Surgical Treatment of Crohn's Disease Among A2 Patients in the Biological Era: A Single Tertiary Referral Center Experience in Northen Italy

Gastroenterology (2019)

Gabriela Nita Rocco Scalzone Fabrizio Aguzzoli Alessandra Soriano Alberto Colognesi

Colorectal Surgery

10.1016/s0016-5085(19)40695-1

Cite

Citations (0)

P03-019 - Anakinra for sweet syndrome treatment

Pediatric Rheumatology (2013)

G Passaro Lucia Cerrito M Giovinale A Marinaro Alessandra Soriano

Sweet syndrome (SS) is a rare autoinflamamtory neutrophilic dermatosis, sometimes associated with hematologic malignancies. We describe two cases of SS related to hematologic diseases successfully treated with an interleukin-1 (IL-1) receptor antagonist (Anakinra).

Sweet's syndrome

Sweet Syndrome

10.1186/1546-0096-11-s1-a217

Cite

Citations (2)

Subcutaneous marginal zone lymphoma: an unusual lipoma-like presentation

Annals of Hematology (2020)

Magda Zanelli Maurizio Zizzo Francesca Sanguedolce Alessandra Soriano Giovanni Martino

Hematology

Presentation (obstetrics)

10.1007/s00277-020-04011-8

Cite

Citations (0)

Correction: Corrigendum: Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy

Scientific Reports (2017)

F. David Carmona Patrick Coit Güher Saruhan‐Direskeneli José Hernández‐Rodríguez María C. Cid

Scientific Reports 7: Article number: 43953; published online: 09 March 2017; updated: 05 April 2017 In this Article, Javier Martin is incorrectly listed as being affiliated with “Departamento de Genética e Instituto de Biotecnología, Universidad de Granada, Granada 18016, Spain”. The correct affiliation is listed below:

10.1038/srep46012

Cite

Citations (6)

Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients

Journal of Autoimmunity (2018)

A. Mékinian Matthieu Resche‐Rigon Cloé Comarmond Alessandra Soriano J. Constans

Tocilizumab

Takayasu Arteritis

10.1016/j.jaut.2018.04.002

Cite

Citations (71)

Survival in patients with chronic hepatitis C and mild-moderate fibrosis according to antiviral treatment response

Journal of Hepatology (2017)

Marc Puigvehí S. Coll A. Raga Alessandra Soriano Núria Cañete

Antiviral Treatment

Hepatitis C

10.1016/s0168-8278(17)31385-5

Cite

Citations (0)

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 2: Clinic–Pathologic Correlations

Cells (2021)

Andrea Palicelli Martina Bonacini Stefania Croci Cristina Magi‐Galluzzi Sofía Cañete‐Portillo

Many studies have investigated the potential prognostic and predictive role of PD-L1 in prostatic carcinoma (PC). We performed a systematic literature review (PRISMA guidelines) to critically evaluate human tissue-based studies (immunohistochemistry, molecular analysis, etc.), experimental research (cell lines, mouse models), and clinical trials. Despite some controversial results and study limitations, PD-L1 expression by tumor cells may be related to clinic-pathologic features of adverse outcome, including advanced tumor stage (high pT, presence of lymph node, and distant metastases), positivity of surgical margins, high Grade Group, and castration resistance. Different PD-L1 positivity rates may be observed in matched primary PCs and various metastatic sites of the same patients. Over-fixation, type/duration of decalcification, and PD-L1 antibody clone may influence the immunohistochemical analysis of PD-L1 on bone metastases. PD-L1 seemed expressed more frequently by castration-resistant PCs (49%) as compared to hormone-sensitive PCs (17%). Some series found that PD-L1 positivity was associated with decreased time to castration resistance. Treatment with ipilimumab, cyclophosphamide/GVAX/degarelix, or degarelix alone may increase PD-L1 expression. Correlation of PD-L1 positivity with overall survival and outcomes related to tumor recurrence were rarely investigated; the few analyzed series produced conflicting results and sometimes showed limitations. Further studies are required. The testing and scoring of PD-L1 should be standardized.

10.3390/cells10113165

Cite

Citations (13)

Primary effusion lymphoma occurring in the setting of transplanted patients: a systematic review of a rare, life-threatening post-transplantation occurrence

BMC Cancer (2021)

Magda Zanelli Francesca Sanguedolce Maurizio Zizzo Andrea Palicelli Maria Chiara Bassi

Abstract Background Primary effusion lymphoma is a rare, aggressive large B-cell lymphoma strictly linked to infection by Human Herpes virus 8/Kaposi sarcoma-associated herpes virus. In its classic form, it is characterized by body cavities neoplastic effusions without detectable tumor masses. It often occurs in immunocompromised patients, such as HIV-positive individuals. Primary effusion lymphoma may affect HIV-negative elderly patients from Human Herpes virus 8 endemic regions. So far, rare cases have been reported in transplanted patients. The purpose of our systematic review is to improve our understanding of this type of aggressive lymphoma in the setting of transplantation, focusing on epidemiology, clinical presentation, pathological features, differential diagnosis, treatment and outcome. The role of assessing the viral serological status in donors and recipients is also discussed. Methods We performed a systematic review adhering to the PRISMA guidelines. The literature search was conducted on PubMed/MEDLINE, Web of Science, Scopus, EMBASE and Cochrane Library, using the search terms “primary effusion lymphoma” and “post-transplant”. Results Our search identified 13 cases of post-transplant primary effusion lymphoma, predominantly in solid organ transplant recipients (6 kidney, 3 heart, 2 liver and 1 intestine), with only one case after allogenic bone marrow transplantation. Long-term immunosuppression is important in post-transplant primary effusion lymphoma commonly developing several years after transplantation. Kaposi Sarcoma occurred in association with lymphoma in 4 cases of solid organ recipients. The lymphoma showed the classical presentation with body cavity effusions in absence of tumor masses in 10 cases; 2 cases presented as solid masses, lacking effusions and one case as effusions associated with multiple organ involvement. Primary effusion lymphoma occurring in the setting of transplantation was more often Epstein Barr-virus negative. The prognosis was poor. In addition to chemotherapy, reduction of immunosuppressive treatment, was generally attempted. Conclusions Primary effusion lymphoma is a rare, but often fatal post-transplant complication. Its rarity and the difficulty in achieving the diagnosis may lead to miss this complication. Clinicians should suspect primary effusion lymphoma in transplanted patients, presenting generally with unexplained body cavity effusions, although rare cases with solid masses are described.

Primary effusion lymphoma

Immunosuppression

10.1186/s12885-021-08215-7

Cite

Citations (31)

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment

International Journal of Molecular Sciences (2021)

Andrea Palicelli Stefania Croci Alessandra Bisagni Eleonora Zanetti Dario de Biase

The tumor microenvironment (TME) includes immune (T, B, NK, dendritic), stromal, mesenchymal, endothelial, adipocytic cells, extracellular matrix, and cytokines/chemokines/soluble factors regulating various intracellular signaling pathways (ISP) in tumor cells. TME influences the survival/progression of prostate cancer (PC), enabling tumor cell immune-evasion also through the activation of the PD-1/PD-L1 axis. We have performed a systematic literature review according to the PRISMA guidelines, to investigate how the PD-1/PD-L1 pathway is influenced by TME and ISPs. Tumor immune-escape mechanisms include suppression/exhaustion of tumor infiltrating cytotoxic T lymphocytes, inhibition of tumor suppressive NK cells, increase in immune-suppressive immune cells (regulatory T, M2 macrophagic, myeloid-derived suppressor, dendritic, stromal, and adipocytic cells). IFN-γ (the most investigated factor), TGF-β, TNF-α, IL-6, IL-17, IL-15, IL-27, complement factor C5a, and other soluble molecules secreted by TME components (and sometimes increased in patients' serum), as well as and hypoxia, influenced the regulation of PD-L1. Experimental studies using human and mouse PC cell lines (derived from either androgen-sensitive or androgen-resistant tumors) revealed that the intracellular ERK/MEK, Akt-mTOR, NF-kB, WNT and JAK/STAT pathways were involved in PD-L1 upregulation in PC. Blocking the PD-1/PD-L1 signaling by using immunotherapy drugs can prevent tumor immune-escape, increasing the anti-tumor activity of immune cells.

10.3390/ijms222212330

Cite

Citations (23)

Functional Expression and Characterization of the Assimilatory-Type Sulfite Reductase from Desulfovibrio vulgaris (Hildenborough)

Archives of Biochemistry and Biophysics (1994)

Jing‐He Tan Alessandra Soriano Siu Man Lui J. A. Cowan

Desulfovibrio vulgaris

Sulfite reductase

Desulfovibrio

10.1006/abbi.1994.1340

Cite

Citations (12)